Anzalone Christopher Richard

Chief Executive Officer

Anzalone Christopher Richard has filed 5 SEC Form 4 filings (28 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jan 5, 2026.

On the most recent filing, Anzalone Christopher Richard is listed as Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. Inside the rolling window, Anzalone Christopher Richard reported no open-market purchases and 7 open-market sales totaling $24.0M in ARWR. The largest disclosed transaction in the window is a sale of 130,000 ARWR shares on Dec 15, 2025, worth $9.0M.

Companies traded

Other insiders at ARWR

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$24.0M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ARWRSale$872KJan 5SEC ↗
ARWRSale$3.6MDec 30SEC ↗
ARWRSale$910KDec 23SEC ↗
ARWRSale$861KDec 23SEC ↗
ARWRSale$5.4MDec 19SEC ↗
ARWRSale$9.0MDec 16SEC ↗
ARWRSale$3.4MDec 16SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Anzalone Christopher Richard made?

Anzalone Christopher Richard has filed 5 SEC Form 4 filings (28 transaction rows) across 1 company since 2025.

Which companies does Anzalone Christopher Richard trade?

Anzalone Christopher Richard has filed SEC Form 4 disclosures for 1 company, including ARWR.

When was Anzalone Christopher Richard's most recent SEC Form 4 filing?

Anzalone Christopher Richard's most recent SEC Form 4 filing on Tracefour is dated Jan 5, 2026.

What is Anzalone Christopher Richard's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Anzalone Christopher Richard is listed as Chief Executive Officer.

What is Anzalone Christopher Richard's total buy and sell value in the current window?

Inside the rolling retention window, Anzalone Christopher Richard bought $0 and sold $24.0M based on SEC Form 4 filings.

What was Anzalone Christopher Richard's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 130,000 ARWR shares on 2025-12-15, worth $9.0M, per SEC Form 4 filings.